1164469-60-6
基本信息
物理化学性质
| 储存条件 | -20°C储存 |
| 溶解度 | DMF: 10 mg/mL; DMF:PBS (pH 7.2) (1:4): 0.2 mg/mL; DMSO: 3 mg/mL |
| 形态 | 结晶固体 |
图谱信息
1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol:hydrochloride(1164469-60-6)核磁图(1HNMR)1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol:hydrochloride价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-B0391B | 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol:hydrochloride Naftopidil hydrochloride | 1164469-60-6 | 5 mg | 500元 |
| 2026/09/15 | HY-B0391B | 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol:hydrochloride Naftopidil hydrochloride | 1164469-60-6 | 10 mg | 800元 |
| 2026/09/15 | HY-B0391B | 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol:hydrochloride Naftopidil hydrochloride | 1164469-60-6 | 25 mg | 1410元 |
常见问题列表
|
Alpha-1A adrenergic receptor 3.7 nM (Ki) |
Alpha-1B adrenergic receptor 20 nM (Ki) |
Alpha-1D adrenergic receptor 1.2 nM (Ki) |
Naftopidil hydrochloride suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
Naftopidil hydrochloride (10 μM for PCa cells, 0.1-10 μM for PrSC; 3 days) shows growth inhibitory effects on PCa cells and PrSC.
Naftopidil hydrochloride (50 μM for E9 cells, 25 μM for PrSC; 48 hours) increases the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC.
Cell Proliferation Assay
| Cell Line: | PCa cells, PrSC |
| Concentration: | 10 μM (PCa cells); 0.1 μM, 1 μM, 10 μM (PrSC) |
| Incubation Time: | 3 days |
| Result: | Exhibited growth inhibitory effects on PCa cells and PrSC in dose-dependent manners. |
Western Blot Analysis
| Cell Line: | PCa cells, PrSC |
| Concentration: | 50 μM (E9 cells), 25 μM (PrSC) |
| Incubation Time: | 48 hours |
| Result: | Increased the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC. |
Naftopidil hydrochloride (10 mg/kg; p.o; daily; for 28 days) decreases microvessel density (MVD) in E9+PrSC tumors mice model.
| Animal Model: | Male athymic mice(7-8 weeks), with E9+PrSC xenograft |
| Dosage: | 10 mg/kg |
| Administration: | Oral administration, daily, for 28 days |
| Result: | Decreased tumor weights. |